Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Thomas Neenan
AddedMar 31, 2024
UpdatedMay 31, 2026
Thomas Neenan

Thomas Neenan

Co-Founder, Nanite

CrunchbaseLinkedIn

Thomas Neenan's Career

Nanite
Nanite

Boston, MA, US

Co-Founder
Sideris Pharmaceuticals
Sideris Pharmaceuticals

Lexington, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Thomas Neenan's Career

Nanite
Nanite
Seed$8M142021Boston, MA, US
Co-Founder

Leadership at Nanite

Shashi MurthyShashi MurthyCo-Founder
Sean KevlahanSean KevlahanCo-Founder

Similar to Nanite

NanotransferNanotransferSunnyvale, CA, USDrug Deliveryest. 2021NanotransferSunnyvale, CA, US · est. 2021

Nanotransfer develops versatile, safe, and cost-effective nanoparticle delivery systems for gene therapies, enhancing cellular internalization and specificity.

Pre-Seed · $200k4
Mana.bioMana.bioTel Aviv, Tel Aviv District, ILDrug Delivery, Therapeuticsest. 2021Mana.bioTel Aviv, Tel Aviv District, IL · est. 2021

Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.

Seed · $29.5M
EnvoyaEnvoyaBoston, MA, USBiotechnology, Softwareest. 2022EnvoyaBoston, MA, US · est. 2022

Envoya, a Boston-based software company, innovates life-changing solutions through advanced research and technology.

Pre-Seed · $2M11
Lattice TherapeuticsLattice TherapeuticsWashington, D.C., DC, USDrug Delivery, Therapeuticsest. 2021Lattice TherapeuticsWashington, D.C., DC, US · est. 2021

Lattice Therapeutics: Pioneering non-viral, precision drug delivery for transformative gene therapy.

Seed · $300k3
Sideris Pharmaceuticals
Sideris Pharmaceuticals
$32.6M02012Lexington, MA, US
Co-Founder

Leadership at Sideris Pharmaceuticals

Raymond BergeronRaymond BergeronCo-Founder

Similar to Sideris Pharmaceuticals

Silarus TherapeuticsSilarus TherapeuticsLos Angeles, CA, USTherapeuticsest. 2014Silarus TherapeuticsLos Angeles, CA, US · est. 2014

Developing therapeutics for anemia and iron overload disorders.

Series A · $10M8
Edimer PharmaceuticalsEdimer PharmaceuticalsCambridge, MA, USPharmaceuticalsest. 2009Edimer PharmaceuticalsCambridge, MA, US · est. 2009

US-based Edimer Pharmaceuticals develops treatments to enhance life quality for XLHED patients.

Series B · $40M14
Sirion HoldingsSirion HoldingsTampa, FL, USMedical Devices, Pharmaceuticalsest. 2006Sirion HoldingsTampa, FL, US · est. 2006

Developing pharmaceuticals and medical devices for eye care, including contract services. Founded in 2006, based in Tampa.

Public · $29.2M30
Aria PharmaceuticalsAria PharmaceuticalsPalo Alto, CA, USPharmaceuticalsest. 2014Aria PharmaceuticalsPalo Alto, CA, US · est. 2014

Aria Pharmaceuticals: Pioneering novel therapies for complex diseases in preclinical stages.

Series B · $14.3M38

People Similar to Thomas Neenan

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao